as 05-30-2025 4:00pm EST
Stocks
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Founded: | 2017 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 93.9M | IPO Year: | 2023 |
Target Price: | $18.50 | AVG Volume (30 days): | 984.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.31 | EPS Growth: | N/A |
52 Week Low/High: | $1.45 - $19.50 | Next Earning Date: | 05-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
LXEO Breaking Stock News: Dive into LXEO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
MT Newswires
19 days ago
GlobeNewswire
20 days ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
MT Newswires
2 months ago
MT Newswires
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "LXEO Lexeo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.